AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.
Novartis’ Sandoz business unit saw a strong financial performance in the first quarter of 2022, with overall sales growth of 8 percent, mostly outside of the United States. Sales for the generics and biosimilar unit benefited from what the company called a normalization of the impacts of COVID-19.
Moderna reported $7.2 billion in fourth-quarter revenue and full-year 2021 revenue of $18.5 billion based on sales of the company’s only marketed product, the mRNA vaccine Spikevax for COVID-19.
Abbott Laboratories beat fourth-quarter 2021 profit and sales estimates, aided by robust sales of COVID-19 test kits and strong demand for the company’s diagnostics products, but forecast lower-than-expected COVID-19 testing sales in 2022 due to uncertainties around the future of the pandemic.
Drugmakers Pfizer, BioNTech and Moderna are expected to reap billions of dollars from Covid-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.
Calling herself a “change agent,” GlaxoSmithKline Chief Executive Officer Emma Walmsley outlined plans to transform the pharmaceuticals business of GSK following the expected spin-off of the company’s consumer health division during an investor conference.
Amgen Inc. reported that third-quarter 2020 adjusted profit rose 17% due to stronger sales of drugs such as the osteoporosis treatment Prolia and the psoriasis medication Otezla, bucking challenges from lower drug prices and Covid-19.
The U.S. Justice Department charged Glenmark Pharmaceuticals with conspiring with other generic drug companies to increase and hold prices for the cholesterol drug pravastatin between May 2013 and December 2015.
Teva Pharmaceutical Industries Ltd. revenue in the second quarter of 2018 were $4.7 billion – a decrease of 18%, or 19% in local currency terms – compared to the second quarter of 2017, mainly due to continued price erosion in our U.S. generics business.
Regeneron Pharmaceuticals Inc. reported important commercial progress in the second quarter with continued strong U.S. sales growth for Eylea in retinal diseases and Dupixent in atopic dermatitis.